Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital and the University Health Network, University of Toronto, Toronto, Ontario, Canada.
J Urol. 2011 Feb;185(2):508-13. doi: 10.1016/j.juro.2010.09.072. Epub 2010 Dec 17.
Partial orchiectomy is becoming more accepted for indications such as a metachronous germ cell tumor due to reported oncological control, and minimal functional, physical and psychological morbidity. Most data originate from Europe. Thus, we reviewed our North American experience with such men who underwent partial orchiectomy for a presumed contralateral testicular malignancy.
We identified demographic, clinical, pathological and outcome data on men in our institutional database who underwent partial orchiectomy for presumed testicular malignancy from 1994 to 2009 and had a prior germ cell tumor. Patients were followed with examination, markers and imaging.
We identified 27 men, of whom 17 (63%) had malignancy, including seminoma in 9, teratoma in 3, embryonal lesion in 1, Leydig cell tumor in 3 and carcinoma in situ in 1, and 10 (37%) had benign lesions. Frozen section was accurate, no positive margins were reported and all tumors were stage 1. Carcinoma in situ was found in 9 patients (53%). No perioperative complications were recorded. Management after partial orchiectomy was observation in 12 of 17 cases. Two patients underwent completion orchiectomy for local recurrence of carcinoma in situ only, including chemotherapy in 1. A patient with seminoma elected radiation and 1 required retroperitoneal lymph node dissection for teratoma. The remaining 5 patients with carcinoma in situ were surveilled. Of the men 31% required testosterone substitution. All patients were disease free at a median 5.7-year followup with no local recurrences.
Partial orchiectomy is an option to decrease morbidity in men with a metachronous germ cell tumor. Clearly a definite benefit of partial orchiectomy is that a significant proportion of patients with suspicious testicular lesions did not have malignancy and were definitively treated with an organ sparing approach. However, partial orchiectomy is potentially associated with the need for adjuvant treatment and androgen substitution, which should be discussed with all patients.
由于报道的肿瘤控制效果,以及最小的功能、身体和心理发病率,部分睾丸切除术越来越被接受用于一些适应证,如同时发生的生殖细胞肿瘤。大多数数据来自欧洲。因此,我们回顾了我们在北美对这些因疑似对侧睾丸恶性肿瘤而行部分睾丸切除术的男性的经验。
我们在机构数据库中确定了 1994 年至 2009 年间因疑似睾丸恶性肿瘤而行部分睾丸切除术且之前患有生殖细胞肿瘤的男性的人口统计学、临床、病理和结果数据。患者通过检查、标志物和影像学进行随访。
我们确定了 27 名男性,其中 17 名(63%)患有恶性肿瘤,包括 9 名精原细胞瘤、3 名畸胎瘤、1 名胚胎性病变、3 名间质细胞瘤和 1 名原位癌,10 名(37%)患有良性病变。冷冻切片准确,未报告阳性边缘,所有肿瘤均为 1 期。9 例(53%)发现原位癌。未记录围手术期并发症。17 例中有 12 例在部分睾丸切除术后行观察治疗。仅因局部复发原位癌而行根治性睾丸切除术 2 例,其中 1 例接受化疗。1 例精原细胞瘤患者选择放疗,1 例畸胎瘤患者行腹膜后淋巴结清扫术。其余 5 例原位癌患者接受监测。27 例患者中有 31%需要睾酮替代治疗。在中位随访 5.7 年后,所有患者均无疾病复发。
部分睾丸切除术是治疗同时发生的生殖细胞肿瘤患者减少发病率的一种选择。显然,部分睾丸切除术的一个明确益处是,很大一部分可疑睾丸病变的患者没有恶性肿瘤,并通过保留器官的方法得到明确治疗。然而,部分睾丸切除术可能与需要辅助治疗和雄激素替代治疗相关,这应该与所有患者讨论。